This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Neuroleptic malignant syndrome

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Malignant neuroleptic syndrome is a rare, potentially fatal idiosyncratic reaction occurring in response to neuroleptic drug therapy. It has been reported for haloperidol, chlorpromazine and flupenthixol decanoate.

The syndrome lasts 5-10 days after the discontinuation of drug therapy during which time ITU support is necessary (1)

There is no proven treatment though bromocriptine and dantrolene have been used.

This syndrome can also occur in patients with Parkinson's disease following withdrawal of levodopa or dopamine antagonists or by the addition of lithium (2).

Reference:

  • (1) BMJ editorial (1993). How "malignant" is the neuroleptic malignant syndrome.BMJ, 307, 1223-4.
  • (2) Prescriber (2001), 12 (5), 43-8.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.